Statistics from Altmetric.com
Churg-Strauss syndrome (CSS) is a disorder characterised by hypereosinophilia and systemic vasculitis occurring in people with asthma and allergic rhinitis. Corticosteroids in combination with a cytotoxic agent are the most effective treatment for CSS. Rituximab, a genetically engineered chimeric anti-CD20 monoclonal antibody has recently been tried with favourable responses in chronic immunological diseases.1 Several published reports have shown its effectiveness in ANCA mediated vasculitides.2,3 We present a patient with CSS who responded well to rituximab after conventional treatments had failed.
A 49 year old, white male patient with a long history of asthma presented in 2000 with inflammatory polyarthritis, bilateral scleritis, and negative autoantibodies. He was managed as a patient with seronegative …